<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Pediatric Uveitic Glaucoma - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjXey1YCBZ4V7jnEixbQAAABo","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Pediatric_Uveitic_Glaucoma","wgTitle":"Pediatric Uveitic Glaucoma","wgCurRevisionId":84526,"wgRevisionId":84526,"wgArticleId":19131,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma","Pediatric Ophthalmology/Strabismus"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Pediatric_Uveitic_Glaucoma","wgRelevantArticleId":19131,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],
"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},
"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Pediatric uveitic glaucoma is a relatively rare condition that follows a course similar to the adult disease process but with its own unique considerations.  This article reviews the current data relevant for understanding and managing glaucoma secondary to uveitis in the pediatric patient."/>
<meta name="date" content="2022-08-20"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Pediatric Uveitic Glaucoma" href="/w/index.php?title=Special:ExportRDF/Pediatric_Uveitic_Glaucoma&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Pediatric_Uveitic_Glaucoma rootpage-Pediatric_Uveitic_Glaucoma layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Pediatric+Uveitic+Glaucoma" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Pediatric+Uveitic+Glaucoma" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzyypwpc"></button>
					<div class="collapse navbar-collapse hbpzyypwpc" id="hbpzyypwpc">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Pediatric_Uveitic_Glaucoma" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Pediatric_Uveitic_Glaucoma&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Pediatric_Uveitic_Glaucoma&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Pediatric_Uveitic_Glaucoma&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Pediatric_Uveitic_Glaucoma&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Pediatric_Uveitic_Glaucoma#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Pediatric Uveitic Glaucoma</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Andrew.Brown" title="User:Andrew.Brown">Andrew D. Brown</a>,&#8201;<a href="/User:Ahmed.Sallam" title="User:Ahmed.Sallam">Ahmed Sallam, MD PhD FRCOphth</a>,&#8201;<a href="/User:Abdelrahman.Elhusseiny" title="User:Abdelrahman.Elhusseiny">Abdelrahman M. Elhusseiny, MD, MSc</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Grace.Prakalapakorn" title="User:Grace.Prakalapakorn">S. Grace Prakalapakorn, MD, MPH</a>,&#160;<a href="/User:Allison.Umfress" title="User:Allison.Umfress">Allison Umfress, MD</a>,&#160;<a href="/User:Abdelrahman.Elhusseiny" title="User:Abdelrahman.Elhusseiny">Abdelrahman M. Elhusseiny, MD, MSc</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Allison.Umfress" title="User:Allison.Umfress">Allison Umfress, MD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Update Pending</b>
</div>
</div>&#160;by <a href="/User:Allison.Umfress" title="User:Allison.Umfress">Allison Umfress, MD</a> on August 21, 2022.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Pediatric_Uveitic_Glaucoma&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Pediatric_Uveitic_Glaucoma&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table> </div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Background"><span class="tocnumber">1</span> <span class="toctext">Background</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Pathophysiology"><span class="tocnumber">2</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#Management"><span class="tocnumber">3</span> <span class="toctext">Management</span></a></li>
<li class="toclevel-1 tocsection-4"><a href="#Medical_Therapy"><span class="tocnumber">4</span> <span class="toctext">Medical Therapy</span></a>
<ul>
<li class="toclevel-2 tocsection-5"><a href="#Beta-blockers"><span class="tocnumber">4.1</span> <span class="toctext">Beta-blockers</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Carbonic_anhydrase_inhibitors_.28CAI.29"><span class="tocnumber">4.2</span> <span class="toctext">Carbonic anhydrase inhibitors (CAI)</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Prostaglandin_analogs_.28PGA.29"><span class="tocnumber">4.3</span> <span class="toctext">Prostaglandin analogs (PGA)</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#Alpha-adrenergic_agonists"><span class="tocnumber">4.4</span> <span class="toctext">Alpha-adrenergic agonists</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Parasympathomimetics"><span class="tocnumber">4.5</span> <span class="toctext">Parasympathomimetics</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-10"><a href="#Surgical_Therapy"><span class="tocnumber">5</span> <span class="toctext">Surgical Therapy</span></a>
<ul>
<li class="toclevel-2 tocsection-11"><a href="#Angle_Surgery"><span class="tocnumber">5.1</span> <span class="toctext">Angle Surgery</span></a>
<ul>
<li class="toclevel-3 tocsection-12"><a href="#Goniotomy"><span class="tocnumber">5.1.1</span> <span class="toctext">Goniotomy</span></a></li>
<li class="toclevel-3 tocsection-13"><a href="#Trabeculotomy"><span class="tocnumber">5.1.2</span> <span class="toctext">Trabeculotomy</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-14"><a href="#Trabeculectomy"><span class="tocnumber">5.2</span> <span class="toctext">Trabeculectomy</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#Deep_sclerectomy"><span class="tocnumber">5.3</span> <span class="toctext">Deep sclerectomy</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Glaucoma_drainage_devices_.28GDD.29"><span class="tocnumber">5.4</span> <span class="toctext">Glaucoma drainage devices (GDD)</span></a></li>
<li class="toclevel-2 tocsection-17"><a href="#Cyclodestructive_procedures"><span class="tocnumber">5.5</span> <span class="toctext">Cyclodestructive procedures</span></a></li>
<li class="toclevel-2 tocsection-18"><a href="#Minimally_invasive_glaucoma_surgery_.28MIGS.29"><span class="tocnumber">5.6</span> <span class="toctext">Minimally invasive glaucoma surgery (MIGS)</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-19"><a href="#Table_Summary"><span class="tocnumber">6</span> <span class="toctext">Table Summary</span></a></li>
<li class="toclevel-1 tocsection-20"><a href="#References"><span class="tocnumber">7</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Background">Background</span></h1>
<p>Pediatric uveitis is a relatively rare condition with the majority of cases being idiopathic. The most common identifiable cause of pediatric uveitis is juvenile idiopathic arthritis (JIA); 14-47% of all pediatric uveitis cases are due to JIA.<sup id="cite_ref-1" class="reference"><a href="#cite_note-1">&#91;1&#93;</a></sup><sup id="cite_ref-2" class="reference"><a href="#cite_note-2">&#91;2&#93;</a></sup><sup id="cite_ref-3" class="reference"><a href="#cite_note-3">&#91;3&#93;</a></sup> Population-based studies in North America and Europe estimate the prevalence of pediatric uveitis to be approximately 30 cases per 100,000 population.<sup id="cite_ref-4" class="reference"><a href="#cite_note-4">&#91;4&#93;</a></sup>
</p><p>Studies have reported that between 5-42% of those pediatric uveitis patients will develop glaucoma or ocular hypertension.<sup id="cite_ref-:0_5-0" class="reference"><a href="#cite_note-:0-5">&#91;5&#93;</a></sup><sup id="cite_ref-:1_6-0" class="reference"><a href="#cite_note-:1-6">&#91;6&#93;</a></sup><sup id="cite_ref-7" class="reference"><a href="#cite_note-7">&#91;7&#93;</a></sup><sup id="cite_ref-8" class="reference"><a href="#cite_note-8">&#91;8&#93;</a></sup><sup id="cite_ref-:3_9-0" class="reference"><a href="#cite_note-:3-9">&#91;9&#93;</a></sup><sup id="cite_ref-:4_10-0" class="reference"><a href="#cite_note-:4-10">&#91;10&#93;</a></sup> 5.3-19% of all pediatric glaucoma cases are caused by uveitis.<sup id="cite_ref-:0_5-1" class="reference"><a href="#cite_note-:0-5">&#91;5&#93;</a></sup><sup id="cite_ref-:1_6-1" class="reference"><a href="#cite_note-:1-6">&#91;6&#93;</a></sup><sup id="cite_ref-:2_11-0" class="reference"><a href="#cite_note-:2-11">&#91;11&#93;</a></sup> 
</p>
<h1><span class="mw-headline" id="Pathophysiology">Pathophysiology</span></h1>
<p>Pediatric uveitic glaucoma progresses similarly to the adult course of the disease.<sup id="cite_ref-:0_5-2" class="reference"><a href="#cite_note-:0-5">&#91;5&#93;</a></sup> Chronic inflammation drives pathological changes to the iridocorneal angle, elevating intraocular pressure (IOP) which if left untreated leads to glaucomatous optic neuropathy.<sup id="cite_ref-:5_12-0" class="reference"><a href="#cite_note-:5-12">&#91;12&#93;</a></sup> The resulting glaucoma can be of the open-angle or closed-angle variety. In open-angle uveitic glaucoma, the cellular inflammatory materials, proteins, or chemical mediators within the eye plug the trabecular meshwork with subsequent aqueous outflow obstruction.<sup id="cite_ref-:2_11-1" class="reference"><a href="#cite_note-:2-11">&#91;11&#93;</a></sup> Other mechanisms include trabeculitis, altered vascular permeability, or steroid-induced ocular hypertension/glaucoma. Chronic inflammation of the trabecular meshwork leads to permanent scarring.<sup id="cite_ref-13" class="reference"><a href="#cite_note-13">&#91;13&#93;</a></sup> Angle-closure glaucoma results from peripheral anterior synechiae (PAS), posterior synechiae, or fibrinous membrane formation with pupillary block.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14">&#91;14&#93;</a></sup> 
</p><p>Steroid-induced IOP elevation has been reported in one-fifth of children treated with different forms of corticosteroids.  Steroid-induced ocular hypertension in children tends to be more aggressive with earlier and more rapid glaucomatous progression if left untreated. 
</p><p>Increased duration and severity of the intraocular inflammation have been associated with more severe presentations of glaucoma.<sup id="cite_ref-:5_12-1" class="reference"><a href="#cite_note-:5-12">&#91;12&#93;</a></sup> Less commonly, intermediate, and posterior uveitis may lead to glaucoma but infrequently compared to anterior uveitis.<sup id="cite_ref-:5_12-2" class="reference"><a href="#cite_note-:5-12">&#91;12&#93;</a></sup><sup id="cite_ref-15" class="reference"><a href="#cite_note-15">&#91;15&#93;</a></sup> Glaucomatous changes to the optic nerve can occur rapidly but often present ten or more years after the initial onset of uveitis.<sup id="cite_ref-:3_9-1" class="reference"><a href="#cite_note-:3-9">&#91;9&#93;</a></sup> 
</p>
<h1><span class="mw-headline" id="Management">Management</span></h1>
<p>Treating the systemic inflammatory condition and controlling the uveitis are central to preventing subsequent glaucoma and ocular hypertension. Effectively managing ocular inflammation early in the course of disease reduces the risk of secondary glaucoma.<sup id="cite_ref-:3_9-2" class="reference"><a href="#cite_note-:3-9">&#91;9&#93;</a></sup><sup id="cite_ref-:4_10-1" class="reference"><a href="#cite_note-:4-10">&#91;10&#93;</a></sup> Co-management with rheumatology will often be necessary given pediatric uveitic glaucoma’s strong correlation with systemic inflammatory conditions.
</p><p>In addition to controlling inflammation, lowering IOP is the gold standard for minimizing the progression of glaucoma.<sup id="cite_ref-16" class="reference"><a href="#cite_note-16">&#91;16&#93;</a></sup> Data on target IOP in the pediatric patient is scarce, with most information coming from primary congenital glaucoma (PCG) treatment. Children undergoing IOP lowering surgery for PCG achieved stability of their neuropathy between 6-15 mmHg.<sup id="cite_ref-17" class="reference"><a href="#cite_note-17">&#91;17&#93;</a></sup> Glaucomatous changes to the optic nerve or visual field in older children can be used as evidence to modify the target IOP.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18">&#91;18&#93;</a></sup>
</p><p>In the setting of uveitis and steroid use it is difficult to determine whether the rise in IOP is a result of inflammation or steroid-induced ocular hypertension. In the presence of active inflammation the rise in IOP is usually secondary to uveitis. Steroid frequency should be increased to control inflammation and subsequently the IOP will lower.  However, in absence of inflammation, ocular hypertension is most likely due to steroid response and lowering the dose or cessation of steroids may be needed.<sup id="cite_ref-19" class="reference"><a href="#cite_note-19">&#91;19&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Medical_Therapy">Medical Therapy</span></h1>
<p>Medical therapy consists of topical eye drops in combination or monotherapy. It is essential to consider that systemic drug absorption is greater in children than in adults. Increased drug plasma levels put them at an increased risk for adverse effects. Punctal occlusion and gel formulations are recommended to minimize risk.<sup id="cite_ref-:0_5-3" class="reference"><a href="#cite_note-:0-5">&#91;5&#93;</a></sup><sup id="cite_ref-20" class="reference"><a href="#cite_note-20">&#91;20&#93;</a></sup> Studies analyzing success rates of topical medications alone in pediatric uveitic glaucoma showed success in only 17% and 26% of patients.<sup id="cite_ref-:3_9-3" class="reference"><a href="#cite_note-:3-9">&#91;9&#93;</a></sup><sup id="cite_ref-21" class="reference"><a href="#cite_note-21">&#91;21&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Beta-blockers">Beta-blockers</span></h2>
<p>(Timolol, Betaxolol) 
</p><p>Timolol is considered a first-line monotherapy that is generally well tolerated.<sup id="cite_ref-:6_22-0" class="reference"><a href="#cite_note-:6-22">&#91;22&#93;</a></sup> Timolol gel-forming solution’s once-a-day timing promotes good compliance. Systemic side effects include hypotension, bradycardia, and bronchospasms and are therefore contraindicated in children with arrhythmias, asthma, or apnea. Betaxolol is a selective β-2 antagonist that reduces the risk of side effects. β -blockers’ mechanism of action is decreased production of aqueous humor from the ciliary body. 
</p>
<h2><span id="Carbonic_anhydrase_inhibitors_(CAI)"></span><span class="mw-headline" id="Carbonic_anhydrase_inhibitors_.28CAI.29">Carbonic anhydrase inhibitors (CAI)</span></h2>
<p>(Dorzolamide, Brinzolamide, Acetazolamide) 
</p><p>Topical CAIs Dorzolamide and Brinzolamide are most often used as an adjunct therapy in combination with a β-blocker when monotherapy does not reach the target IOP.<sup id="cite_ref-:6_22-1" class="reference"><a href="#cite_note-:6-22">&#91;22&#93;</a></sup> They are prescribed twice daily (BID) in combination or three times daily (TID) as monotherapy. Oral acetazolamide has also been shown to effectively lower IOP but is associated with more side effects. Contraindications include hypokalemia, hyponatremia, and sulfonamide hypersensitivity. The mechanism of action of CAIs is decreased production of aqueous humor from the ciliary body. 
</p>
<h2><span id="Prostaglandin_analogs_(PGA)"></span><span class="mw-headline" id="Prostaglandin_analogs_.28PGA.29">Prostaglandin analogs (PGA)</span></h2>
<p>(Latanoprost, Travoprost) 
</p><p>PGAs are prescribed as once-daily topical monotherapy with a mechanism of action of increasing uveoscleral outflow.<sup id="cite_ref-:6_22-2" class="reference"><a href="#cite_note-:6-22">&#91;22&#93;</a></sup><sup id="cite_ref-:7_23-0" class="reference"><a href="#cite_note-:7-23">&#91;23&#93;</a></sup> Recent  data showed that patients already affected by uveitis and glaucoma are not at an increased risk for uveitis and CME while using PGAs.<sup id="cite_ref-24" class="reference"><a href="#cite_note-24">&#91;24&#93;</a></sup><sup id="cite_ref-25" class="reference"><a href="#cite_note-25">&#91;25&#93;</a></sup><sup id="cite_ref-26" class="reference"><a href="#cite_note-26">&#91;26&#93;</a></sup>
</p><p>A retrospective review by Bello et al. examined the use of PGAs in children with glaucoma to determine their likelihood of causing uveitis. Included in the study were 147 eyes (103 patients) with glaucoma. Of the 20 eyes (15 patients) with a history of chronic uveitis, five eyes (five patients) experienced recurrences that were explained by an improper tapering of their topical steroid or methotrexate.<sup id="cite_ref-27" class="reference"><a href="#cite_note-27">&#91;27&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Alpha-adrenergic_agonists">Alpha-adrenergic agonists</span></h2>
<p>(Brimonidine, Apraclonidine) 
</p><p>Brimonidine is not preferred in pediatric patients due to its ability to cross the blood brain barrier and commonly causes sleepiness and lethargy.<sup id="cite_ref-:6_22-3" class="reference"><a href="#cite_note-:6-22">&#91;22&#93;</a></sup> It is absolutely contraindicated in children under two years old and in children with cardiovascular disorders due to potentially life-threatening complications. Children older than six years old and weighing more than 20kg have less risk of side effects. Their mechanism of action is decreased production of aqueous humor from the ciliary body and increased uveoscleral outflow. They are prescribed BID.<sup id="cite_ref-:7_23-1" class="reference"><a href="#cite_note-:7-23">&#91;23&#93;</a></sup> Apraclonidine is used three times daily short-term to control IOP before and after glaucoma surgeries.<sup id="cite_ref-:7_23-2" class="reference"><a href="#cite_note-:7-23">&#91;23&#93;</a></sup><sup id="cite_ref-:8_28-0" class="reference"><a href="#cite_note-:8-28">&#91;28&#93;</a></sup> In contrast to Brimonidine, several studies have demonstrated the safety of Apraclonidine use in both infants and children.<sup id="cite_ref-29" class="reference"><a href="#cite_note-29">&#91;29&#93;</a></sup><sup id="cite_ref-30" class="reference"><a href="#cite_note-30">&#91;30&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Parasympathomimetics">Parasympathomimetics</span></h2>
<p>(Pilocarpine) 
</p><p>These are primarily used before and after surgery or in patients with aphakia. They are contraindicated in active uveitis.<sup id="cite_ref-31" class="reference"><a href="#cite_note-31">&#91;31&#93;</a></sup> 
</p>
<h1><span class="mw-headline" id="Surgical_Therapy">Surgical Therapy</span></h1>
<h2><span class="mw-headline" id="Angle_Surgery">Angle Surgery</span></h2>
<h3><span class="mw-headline" id="Goniotomy">Goniotomy</span></h3>
<p>Goniotomy utilizes an internal approach to open the trabecular meshwork with a sharp instrument or laser to improve outflow. Both goniotomy and trabeculotomy procedures have exhibited similar success rates in pediatric glaucoma dating back to 1984.<sup id="cite_ref-:0_5-4" class="reference"><a href="#cite_note-:0-5">&#91;5&#93;</a></sup><sup id="cite_ref-32" class="reference"><a href="#cite_note-32">&#91;32&#93;</a></sup>
</p><p>A study conducted by Ho and colleagues evaluated the efficacy of goniotomy in 31 pediatric uveitic glaucoma patients (40 eyes).<sup id="cite_ref-:9_33-0" class="reference"><a href="#cite_note-:9-33">&#91;33&#93;</a></sup> Surgical success was achieved in 72% of eyes at final follow up (98.9 months).&#160; The mean IOP in the surgical success group decreased from 35.8±5.9 mmHg to 14.7±2.9 mmHg at the final follow-up (P&lt;.001). 22 eyes (55%) maintained an IOP of &lt;21 without glaucoma medications at final follow-up. Predictors of success were phakic lens status (P=.004) and age &lt;10 years old (P=.03). The main complication was intraoperative hyphema (80%) that resolved within one week.
</p><p>Freedman et al. evaluated 16 eyes of 12 pediatric uveitic glaucoma patients who have undergone goniotomy.<sup id="cite_ref-:8_28-1" class="reference"><a href="#cite_note-:8-28">&#91;28&#93;</a></sup> The mean pre-operative IOP was 31.5±4.3 mmHg and decreased to 12±12.5 mmHg at final follow-up (mean 32.4 months) (P&lt;.0001). Post-operative transient hyphema occurred in 9 eyes (56%).
</p>
<h3><span class="mw-headline" id="Trabeculotomy">Trabeculotomy</span></h3>
<p>Wang et al. demonstrated a statistically significant decrease in IOP from 31.4±7.6 mmHg to 15.0±3.6 mmHg post-operatively (P&lt;.001) at final follow-up (mean 31 months). <sup id="cite_ref-:10_34-0" class="reference"><a href="#cite_note-:10-34">&#91;34&#93;</a></sup>There was a considerable decrease in post-operative glaucoma medication requirements from 4.2±1 to 0.4±1 at final follow-up (P&lt;.001).
</p>
<h2><span class="mw-headline" id="Trabeculectomy">Trabeculectomy</span></h2>
<p>Wiese et al. studied 21 eyes (17 children) with uveitic glaucoma who underwent mitomycin-C augmented (MMC) trabeculectomy.<sup id="cite_ref-:11_35-0" class="reference"><a href="#cite_note-:11-35">&#91;35&#93;</a></sup> They reported that 70% of children had an IOP &lt;15 mmHg after 1 year post-operatively. Heinz et al. presented 16 eyes (16 patients) who underwent trabeculectomy and reported a reduction in the mean IOP from 28.3±5.7 mmHg pre-operatively to 11.6±4.7 mmHg at one year post-operatively.<sup id="cite_ref-:12_36-0" class="reference"><a href="#cite_note-:12-36">&#91;36&#93;</a></sup> 
</p><p>The essential nature of tumor necrosis factor (TNF) inhibition in the trabeculectomy procedure for JIA-related uveitic glaucoma was suggested in 2015 by Leinonen et al.<sup id="cite_ref-:13_37-0" class="reference"><a href="#cite_note-:13-37">&#91;37&#93;</a></sup> 29 eyes (29 patients) were included in the study. Compared to trabeculectomy with MMC alone, trabeculectomy with MMC and TNF inhibitors was associated with more successful outcomes (P=.003). Success was defined as IOP ≤21mmHg without glaucoma medications and without the need for further IOP lower surgeries. By Kaplan-Meier analysis, 5-year success rates for trabeculectomy with MMC alone was only 16%, while 5-year success for trabeculectomy with MMC and TNF inhibitors was 73%. 
</p>
<h2><span class="mw-headline" id="Deep_sclerectomy">Deep sclerectomy</span></h2>
<p>A retrospective review of 8 eyes (8 patients) conducted by Heinz et al. reported a mean reduction of IOP from 30.3±6.3 mmHg to 18.5±11.4 mmHg at one-year post-operatively.<sup id="cite_ref-:12_36-1" class="reference"><a href="#cite_note-:12-36">&#91;36&#93;</a></sup> They compared the MMC-augmented trabeculectomy group (16 eyes) to those who underwent deep sclerectomy. The deep sclerectomy group was associated with a statistically significant higher rate of failure when compared to trabeculectomy (P=.041). Deep sclerectomy failed to achieve IOP ≤21 mmHg without medications in 50% of eyes at final follow up (mean 29.4 months) while trabeculectomy failed to achieve IOP ≤21 mmHg without medications in only 6% of eyes at final follow up (mean 21.5 months). 
</p>
<h2><span id="Glaucoma_drainage_devices_(GDD)"></span><span class="mw-headline" id="Glaucoma_drainage_devices_.28GDD.29">Glaucoma drainage devices (GDD)</span></h2>
<p>The first study of GDD in JIA-associated glaucoma was conducted by Välimäki et al. including 27 eyes (19 patients) who underwent Molteno GDD.<sup id="cite_ref-:14_38-0" class="reference"><a href="#cite_note-:14-38">&#91;38&#93;</a></sup> The mean IOP was decreased from 38.3±5.6 mmHg pre-operatively to 14.4±4.3 mmHg (P&lt;.001) at the final follow-up (mean 40 months). Glaucoma medications were reduced from 2.7±0.9 pre-operatively to 1.0±1.1 post-operatively (P&lt;.001). 90% of patients achieved success which was defined as IOP ≤22 mmHg and ≥6 mmHg without loss of light perception and equal or fewer glaucoma medications at 52 months post-operatively. 
</p><p>Kafkala et al. evaluated the efficacy of Ahmed glaucoma valve in 7 pediatric uveitic glaucoma eyes (6 patients).<sup id="cite_ref-:15_39-0" class="reference"><a href="#cite_note-:15-39">&#91;39&#93;</a></sup> At the final follow-up (mean 36.8 months), all 7 eyes had an IOP between 7 and 18 mmHg. Glaucoma medications were decreased from 3±0.82 to 0.71±0.75 at final follow-up (P=.001).
</p><p>A case series conducted Bohnsack et al. reported a success rate of 80% at final follow-up (mean 102 months) after GDD implantation in 5 eyes with pediatric uveitic glaucoma.<sup id="cite_ref-:16_40-0" class="reference"><a href="#cite_note-:16-40">&#91;40&#93;</a></sup> Success was defined as a final IOP &lt;21 mmHg without inflammation, serious complications or need for further IOP lowering surgery. The mean IOP was decreased from 27.2±7.6 mmHg pre-operatively to 13.6±3.2 mmHg at the final follow-up (mean 57.6 months). Glaucoma medications decreased from 3.0 ±1.2 pre-operatively to 0.6 ±0.9 at final follow up. The data included both Ahmed and Baerveldt devices and reported no intraoperative complications.
</p><p>In patients with co-existing corneal pathologies, combined pars-plana vitrectomy and sulcus placement of the GDD may be needed.
</p>
<h2><span class="mw-headline" id="Cyclodestructive_procedures">Cyclodestructive procedures</span></h2>
<p>A retrospective review conducted by Heinz et al. included 19 pediatric uveitic open-angle glaucoma eyes who were treated with trans-scleral cyclophotocoagulation as a primary procedure.<sup id="cite_ref-:17_41-0" class="reference"><a href="#cite_note-:17-41">&#91;41&#93;</a></sup> IOP was decreased by 8.8 mmHg after three sessions of treatments (P=.018), but only 6 eyes (32%) achieved IOP ≤21 with glaucoma medication at the final follow-up (mean 10.1 months). None of the patients developed hypotony or serious adverse events. 
</p>
<h2><span id="Minimally_invasive_glaucoma_surgery_(MIGS)"></span><span class="mw-headline" id="Minimally_invasive_glaucoma_surgery_.28MIGS.29">Minimally invasive glaucoma surgery (MIGS)</span></h2>
<p>Sachdev et al. published a case series in 2020 showing promising results from gonioscopy-assisted transluminal trabeculotomy (GATT) in JIA-associated glaucoma. Sachdev et al. presented three eyes from three patients with a 40% to 66% reduction in mean IOP following GATT.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42">&#91;42&#93;</a></sup> The procedure resulted in one patient requiring fewer glaucoma medications post-operatively, and two patients were able to discontinue their glaucoma medications altogether. 
</p>
<h1><span class="mw-headline" id="Table_Summary">Table Summary</span></h1>
<p>Table 1: Summary of the retrospective case reviews analyzing surgical therapy outcomes specific to pediatric uveitic glaucoma.  
</p>
<table class="wikitable">
<caption>Caption text
</caption>
<tbody><tr>
<th><b>Name of study, year published⬇</b></th>
<th><b>Procedure</b>
</th>
<th><b># of eyes (# of patients)</b>
</th>
<th><b>Pre-operative IOP</b> <b>(Mean±SD)</b></th>
<th><b>Post-operative IOP</b> <b>(Mean±SD)</b></th>
<th><b>Pre-operative medications</b> <b>(Mean±SD)</b></th>
<th><b>Post-operative medications</b> <b>(Mean±SD)</b></th>
<th><b>Follow-up time, months</b>
<p><b>Mean±SD (range)</b>
</p>
</th>
<th><b>Definition of success</b>
</th>
<th><b>Success Rate</b>
</th></tr>
<tr>
<td>Wang et al.<sup id="cite_ref-:10_34-1" class="reference"><a href="#cite_note-:10-34">&#91;34&#93;</a></sup>, 2016</td>
<td>Trabeculotomy</td>
<td>28(22)</td>
<td>31.4±7.6</td>
<td>15±3.6 at final follow-up</td>
<td>4.2±1.1</td>
<td>0.4±1.0</td>
<td>31±17.8</td>
<td>IOP &lt;22 and ≥6 with or without  medications</td>
<td>81.8% at final follow-up
</td></tr>
<tr>
<td>Leinonen et al.<sup id="cite_ref-:13_37-1" class="reference"><a href="#cite_note-:13-37">&#91;37&#93;</a></sup>, 2015
</td>
<td>Trabeculectomy  with MMC</td>
<td>15(15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>96 (12-224.4)</td>
<td>IOP ≤21, without medications or  futher surgery</td>
<td>57% at 1 year, 16% at 5 years, and  0% 10 years
</td></tr>
<tr>
<td>
</td>
<td>Trabeculectomy  with MMC and TNF inhibitors
</td>
<td>14(14)
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>87.6 (12-152.4)
</td>
<td>IOP ≤21, without medications or  futher surgery
</td>
<td>73% at 1 year, 5 years, and 10  years
</td></tr>
<tr>
<td>Wiese et al.<sup id="cite_ref-:11_35-1" class="reference"><a href="#cite_note-:11-35">&#91;35&#93;</a></sup>, 2014
</td>
<td>Trabeculectomy  with MMC</td>
<td>21(17)</td>
<td>31.1±6.7</td>
<td>10.1±4.7 at 1 year</td>
<td></td>
<td></td>
<td>59.5 ± 23.3</td>
<td>1. IOP ≤15 without  medication
<p>2. IOP ≤15 with medication
</p>
</td>
<td>1. 55% at 1 year, 38% at 5  years.
<p>2. 70% at 1 year, 62% at 5 years
</p>
</td></tr>
<tr>
<td>Bohnsack  and Freedman<sup id="cite_ref-:16_40-1" class="reference"><a href="#cite_note-:16-40">&#91;40&#93;</a></sup>, 2013
</td>
<td>GDD (Ahmed and Baerveldt)
</td>
<td>5(5)
</td>
<td>27.2±7.6
</td>
<td>13.6±3.2 at final follow up
</td>
<td>3.0±1.2
</td>
<td>0.6±0.9
</td>
<td>28.8±20.4
</td>
<td>IOP &lt;21 without inflammation,  serious complications or need for further IOP lowering surgery
</td>
<td>80% at final follow-up
</td></tr>
<tr>
<td>
</td>
<td>Goniotomy
</td>
<td>22(22)
</td>
<td>34.0±7.8
</td>
<td>13.5±4.5 at final follow up
</td>
<td>3.3±1.1
</td>
<td>1.5±1.4
</td>
<td>57.6±52.8
</td>
<td>IOP &lt;21 without inflammation,  serious complications or need for further IOP lowering surgery
</td>
<td>76% at 1 year, 57% at 2 years, 48% at 10 years
</td></tr>
<tr>
<td>Heinz et al.<sup id="cite_ref-:12_36-2" class="reference"><a href="#cite_note-:12-36">&#91;36&#93;</a></sup>, 2011</td>
<td>Trabeculectomy</td>
<td>16(16)</td>
<td>28.3±5.7</td>
<td>11.6±4.7 at 1 year</td>
<td>3.3</td>
<td></td>
<td>21.5</td>
<td>1. IOP ≤21 without glaucoma  meds
<p>2. IOP ≤15 without glaucoma meds
</p>
</td>
<td>1. 88% at last visit
<p>2. 75% at last visit
</p>
</td></tr>
<tr>
<td></td>
<td>Modified  deep sclerectomy</td>
<td>8(8)</td>
<td>30.3±6.3</td>
<td>18.5±11.4 at 1 year</td>
<td>3.4</td>
<td></td>
<td>29.4</td>
<td>1. IOP ≤21 without glaucoma  meds
<p>2. IOP ≤15 without glaucoma meds
</p>
</td>
<td>1. 50% at last visit
<p>2. 38% at last visit
</p>
</td></tr>
<tr>
<td>Heinz et al.<sup id="cite_ref-:17_41-1" class="reference"><a href="#cite_note-:17-41">&#91;41&#93;</a></sup>, 2006
</td>
<td>Transscleral  diode laser cyclophotocoagulation</td>
<td>19(12)</td>
<td>30.2±5.5</td>
<td>28.7±6.4 before third treatment</td>
<td>3.3±0.7</td>
<td>2.7±1.6 after third treatment</td>
<td>10.1±9.3 (3–30)</td>
<td>IOP ≤21 with medications</td>
<td>32% at final follow-up
</td></tr>
<tr>
<td>Kafkala et al.<sup id="cite_ref-:15_39-1" class="reference"><a href="#cite_note-:15-39">&#91;39&#93;</a></sup>, 2005</td>
<td>GDD  (Ahmed)</td>
<td>7(6)</td>
<td>37 ± 8</td>
<td>12.1±3.4 at final follow-up</td>
<td>3</td>
<td>0.71</td>
<td>36.8 (6-60)</td>
<td>IOP&#160; &lt;22 and &gt;4 at final 2 follow-ups,  with or without medications</td>
<td>100% at 3 months
</td></tr>
<tr>
<td>Ho et al.<sup id="cite_ref-:9_33-1" class="reference"><a href="#cite_note-:9-33">&#91;33&#93;</a></sup>, 2004</td>
<td>Goniotomy</td>
<td>40(31)</td>
<td>35.8±5.9*</td>
<td>14.7±2.9 at final follow-up*</td>
<td>2.9±1.1</td>
<td>1.6±1.1</td>
<td>98.9±87.8 (2-324)</td>
<td>IOP ≤21 without medications</td>
<td>55% at final follow-up
</td></tr>
<tr>
<td>Freedman et al.<sup id="cite_ref-:8_28-2" class="reference"><a href="#cite_note-:8-28">&#91;28&#93;</a></sup>, 2002
</td>
<td>Goniotomy</td>
<td>16(12)</td>
<td>32.3±4.6</td>
<td>12±2.5 at final follow-up</td>
<td>2.5±1.1</td>
<td>1.4±1.1</td>
<td>32.4 (6-84)</td>
<td>IOP ≤21 after one or two  goniotomies with or without medications</td>
<td>75% at final follow-up
</td></tr>
<tr>
<td>Välimäki et al.<sup id="cite_ref-:14_38-1" class="reference"><a href="#cite_note-:14-38">&#91;38&#93;</a></sup>, 1997</td>
<td>GDD  (Molteno)</td>
<td>27(19)</td>
<td>38.3 ± 5.6</td>
<td>14.4 ± 4.3 at final follow-up</td>
<td>2.7±0.9</td>
<td>1.0 ± 1.1</td>
<td>40 (6-116)</td>
<td>IOP&#160; ≤22 and ≥6 at the final 2 follow-ups, with  equal or fewer medications</td>
<td>89% at final follow-up
</td></tr></tbody></table>
<h1><span class="mw-headline" id="References">References</span></h1>
<p>Add text here
</p>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-1"><span class="mw-cite-backlink"><a href="#cite_ref-1">↑</a></span> <span class="reference-text">Engelhard SB, Bajwa A, Reddy AK. Causes of uveitis in children without juvenile idiopathic arthritis. Clin Ophthalmol. 2015;9:1121-1128. Published 2015 Jun 25. doi:10.2147/OPTH.S83950</span>
</li>
<li id="cite_note-2"><span class="mw-cite-backlink"><a href="#cite_ref-2">↑</a></span> <span class="reference-text">Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol. 2003;135(5):676-680. doi:10.1016/s0002-9394(02)02148-7</span>
</li>
<li id="cite_note-3"><span class="mw-cite-backlink"><a href="#cite_ref-3">↑</a></span> <span class="reference-text">BenEzra D, Cohen E, Maftzir G. Uveitis in children and adolescents. Br J Ophthalmol. 2005;89(4):444-448. doi:10.1136/bjo.2004.050609</span>
</li>
<li id="cite_note-4"><span class="mw-cite-backlink"><a href="#cite_ref-4">↑</a></span> <span class="reference-text">Holland, Gary N, and E Richard Stiehm. “Special considerations in the evaluation and management of uveitis in children.” American journal of ophthalmology vol. 135,6 (2003): 867-78. doi:10.1016/s0002-9394(03)00314-3</span>
</li>
<li id="cite_note-:0-5"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:0_5-0">5.0</a></sup> <sup><a href="#cite_ref-:0_5-1">5.1</a></sup> <sup><a href="#cite_ref-:0_5-2">5.2</a></sup> <sup><a href="#cite_ref-:0_5-3">5.3</a></sup> <sup><a href="#cite_ref-:0_5-4">5.4</a></sup></span> <span class="reference-text">Kalogeropoulos D, Kalogeropoulos C, Moschos MM, Sung V. The Management of Uveitic Glaucoma in Children. Turk J Ophthalmol. 2019;49(5):283-293. doi:10.4274/tjo.galenos.2019.36589</span>
</li>
<li id="cite_note-:1-6"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:1_6-0">6.0</a></sup> <sup><a href="#cite_ref-:1_6-1">6.1</a></sup></span> <span class="reference-text">Paroli MP, Speranza S, Marino M, Pirraglia MP, Pivetti-Pezzi P. Prognosis of juvenile rheumatoid arthritis-associated uveitis. Eur J Ophthalmol. 2003;13(7):616-621. doi:10.1177/112067210301300704</span>
</li>
<li id="cite_note-7"><span class="mw-cite-backlink"><a href="#cite_ref-7">↑</a></span> <span class="reference-text">Sijssens KM, Rothova A, Berendschot TT, de Boer JH. Ocular hypertension and secondary glaucoma in children with uveitis. Ophthalmology. 2006;113(5):853-9.e2. </span>
</li>
<li id="cite_note-8"><span class="mw-cite-backlink"><a href="#cite_ref-8">↑</a></span> <span class="reference-text">Morelle G, Gueudry J, Uettwiller F, et al. Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort. RMD Open. 2019;5(2):e000933. Published 2019 Aug 5. doi:10.1136/rmdopen-2019-000933</span>
</li>
<li id="cite_note-:3-9"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:3_9-0">9.0</a></sup> <sup><a href="#cite_ref-:3_9-1">9.1</a></sup> <sup><a href="#cite_ref-:3_9-2">9.2</a></sup> <sup><a href="#cite_ref-:3_9-3">9.3</a></sup></span> <span class="reference-text">Foster CS, Havrlikova K, Baltatzis S, Christen WG, Merayo-Lloves J. Secondary glaucoma in patients with juvenile rheumatoid arthritis-associated iridocyclitis. Acta Ophthalmol Scand. 2000;78(5):576-579. doi:10.1034/j.1600-0420.2000.078005576.x</span>
</li>
<li id="cite_note-:4-10"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:4_10-0">10.0</a></sup> <sup><a href="#cite_ref-:4_10-1">10.1</a></sup></span> <span class="reference-text">Huynh E, Elhusseiny AM, Nihalani BR. Paediatric anterior uveitis management in the USA: a single-centre, 10-year retrospective chart review exploring the efficacy and safety of systemic immunomodulatory therapy [published online ahead of print, 2022 Jun 1]. Eye (Lond). 2022;10.1038/s41433-022-02121-3. doi:10.1038/s41433-022-02121-3</span>
</li>
<li id="cite_note-:2-11"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:2_11-0">11.0</a></sup> <sup><a href="#cite_ref-:2_11-1">11.1</a></sup></span> <span class="reference-text">Kaur S, Kaushik S, Singh Pandav S. Pediatric Uveitic Glaucoma. J Curr Glaucoma Pract. 2013;7(3):115-117. doi:10.5005/jp-journals-10008-1147</span>
</li>
<li id="cite_note-:5-12"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:5_12-0">12.0</a></sup> <sup><a href="#cite_ref-:5_12-1">12.1</a></sup> <sup><a href="#cite_ref-:5_12-2">12.2</a></sup></span> <span class="reference-text">Kok H, Barton K. Uveitic glaucoma. Ophthalmol Clin North Am. 2002;15(3):375-viii. doi:10.1016/s0896-1549(02)00028-7</span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><a href="#cite_ref-13">↑</a></span> <span class="reference-text">Bodh SA, Kumar V, Raina UK, Ghosh B, Thakar M. Inflammatory glaucoma. Oman J Ophthalmol. 2011;4(1):3-9. doi:10.4103/0974-620X.77655</span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><a href="#cite_ref-14">↑</a></span> <span class="reference-text">Kalogeropoulos D, Sung VC. Pathogenesis of Uveitic Glaucoma. J Curr Glaucoma Pract. 2018;12(3):125-138. doi:10.5005/jp-journals-10028-1257</span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><a href="#cite_ref-15">↑</a></span> <span class="reference-text">Engelhard SB, Patel V, Reddy AK. Intermediate uveitis, posterior uveitis, and panuveitis in the Mid-Atlantic USA. Clin Ophthalmol. 2015;9:1549-1555. Published 2015 Aug 25. doi:10.2147/OPTH.S89428</span>
</li>
<li id="cite_note-16"><span class="mw-cite-backlink"><a href="#cite_ref-16">↑</a></span> <span class="reference-text">Clement CI, Bhartiya S, Shaarawy T. New perspectives on target intraocular pressure. Surv Ophthalmol. 2014;59(6):615-626. doi:10.1016/j.survophthal.2014.04.001</span>
</li>
<li id="cite_note-17"><span class="mw-cite-backlink"><a href="#cite_ref-17">↑</a></span> <span class="reference-text">Sihota R, Sidhu T, Agarwal R, et al. Evaluating target intraocular pressures in primary congenital glaucoma. Indian J Ophthalmol. 2021;69(8):2082-2087. doi:10.4103/ijo.IJO_3473_20</span>
</li>
<li id="cite_note-18"><span class="mw-cite-backlink"><a href="#cite_ref-18">↑</a></span> <span class="reference-text">Sihota R, Angmo D, Ramaswamy D, Dada T. Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol. 2018;66(4):495-505. doi:10.4103/ijo.IJO_1130_17</span>
</li>
<li id="cite_note-19"><span class="mw-cite-backlink"><a href="#cite_ref-19">↑</a></span> <span class="reference-text">Nuyen B, Weinreb RN, Robbins SL. Steroid-induced glaucoma in the pediatric population. <i>J aapos.</i> 2017;21(1):1-6.</span>
</li>
<li id="cite_note-20"><span class="mw-cite-backlink"><a href="#cite_ref-20">↑</a></span> <span class="reference-text">Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91(11):1361-1363. doi:10.1016/s0161-6420(84)34141-0</span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><a href="#cite_ref-21">↑</a></span> <span class="reference-text">Heinz C, Koch JM, Zurek-Imhoff B, Heiligenhaus A. Prevalence of uveitic secondary glaucoma and success of nonsurgical treatment in adults and children in a tertiary referral center. Ocul Immunol Inflamm. 2009;17(4):243-248. doi:10.1080/09273940902913035</span>
</li>
<li id="cite_note-:6-22"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:6_22-0">22.0</a></sup> <sup><a href="#cite_ref-:6_22-1">22.1</a></sup> <sup><a href="#cite_ref-:6_22-2">22.2</a></sup> <sup><a href="#cite_ref-:6_22-3">22.3</a></sup></span> <span class="reference-text">Coppens G, Stalmans I, Zeyen T, Casteels I. The safety and efficacy of glaucoma medication in the pediatric population. J Pediatr Ophthalmol Strabismus. 2009;46(1):12-18. doi:10.3928/01913913-20090101-0</span>
</li>
<li id="cite_note-:7-23"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:7_23-0">23.0</a></sup> <sup><a href="#cite_ref-:7_23-1">23.1</a></sup> <sup><a href="#cite_ref-:7_23-2">23.2</a></sup></span> <span class="reference-text">Moore W, Nischal KK. Pharmacologic management of glaucoma in childhood. Paediatr Drugs. 2007;9(2):71-79. doi:10.2165/00148581-200709020-00001</span>
</li>
<li id="cite_note-24"><span class="mw-cite-backlink"><a href="#cite_ref-24">↑</a></span> <span class="reference-text">Moorthy RS, Moorthy MS, Cunningham ET Jr. Drug-induced uveitis. Curr Opin Ophthalmol. 2018;29(6):588-603. doi:10.1097/ICU.0000000000000530</span>
</li>
<li id="cite_note-25"><span class="mw-cite-backlink"><a href="#cite_ref-25">↑</a></span> <span class="reference-text">Heinz C, Schlote T, Dietlein T, Pillunat L. Glaukom bei Uveitis im Kindesalter [Glaucoma in childhood uveitis]. Klin Monbl Augenheilkd. 2007;224(6):511-515. doi:10.1055/s-2007-963039</span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><a href="#cite_ref-26">↑</a></span> <span class="reference-text">Chang JH, McCluskey P, Missotten T, Ferrante P, Jalaludin B, Lightman S. Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema?. Br J Ophthalmol. 2008;92(7):916-921. doi:10.1136/bjo.2007.131037</span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><a href="#cite_ref-27">↑</a></span> <span class="reference-text">Bello, Nicholas R, et al. “The Risk of Uveitis Due to Prostaglandin Analogs in Pediatric Glaucoma.” Journal of AAPOS, 2022. </span>
</li>
<li id="cite_note-:8-28"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:8_28-0">28.0</a></sup> <sup><a href="#cite_ref-:8_28-1">28.1</a></sup> <sup><a href="#cite_ref-:8_28-2">28.2</a></sup></span> <span class="reference-text">Freedman SF, Rodriguez-Rosa RE, Rojas MC, Enyedi LB. Goniotomy for glaucoma secondary to chronic childhood uveitis. Am J Ophthalmol. 2002;133(5):617-621. doi:10.1016/s0002-9394(02)01344-2</span>
</li>
<li id="cite_note-29"><span class="mw-cite-backlink"><a href="#cite_ref-29">↑</a></span> <span class="reference-text">Wright TM, Freedman SF. Exposure to topical apraclonidine in children with glaucoma. J Glaucoma. 2009;18(5):395-398. doi:10.1097/IJG.0b013e31818624e5</span>
</li>
<li id="cite_note-30"><span class="mw-cite-backlink"><a href="#cite_ref-30">↑</a></span> <span class="reference-text">Eldib AA, Patil P, Nischal KK, Mitchell ER, Hiasat JG, Pihlblad MS. Safety of apraclonidine eye drops in diagnosis of Horner syndrome in an outpatient pediatric ophthalmology clinic. J AAPOS. 2021;25(6):336.e1-336.e4. doi:10.1016/j.jaapos.2021.07.011</span>
</li>
<li id="cite_note-31"><span class="mw-cite-backlink"><a href="#cite_ref-31">↑</a></span> <span class="reference-text">Chang L, Ong EL, Bunce C, Brookes J, Papadopoulos M, Khaw PT. A review of the medical treatment of pediatric glaucomas at Moorfields Eye Hospital. J Glaucoma. 2013;22(8):601-607. doi:10.1097/IJG.0b013e31824d1e2f</span>
</li>
<li id="cite_note-32"><span class="mw-cite-backlink"><a href="#cite_ref-32">↑</a></span> <span class="reference-text">Hoskins HD Jr, Shaffer RN, Hetherington J. Goniotomy vs trabeculotomy. J Pediatr Ophthalmol Strabismus. 1984;21: 153–158.</span>
</li>
<li id="cite_note-:9-33"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:9_33-0">33.0</a></sup> <sup><a href="#cite_ref-:9_33-1">33.1</a></sup></span> <span class="reference-text">Ho CL, Wong EY, Walton DS. Goniosurgery for glaucoma complicating chronic childhood uveitis. Arch Ophthalmol. 2004;122(6):838-844. doi:10.1001/archopht.122.6.838</span>
</li>
<li id="cite_note-:10-34"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:10_34-0">34.0</a></sup> <sup><a href="#cite_ref-:10_34-1">34.1</a></sup></span> <span class="reference-text">Wang Q, Wang J, Fortin E, Hamel P. Trabeculotomy in the Treatment of Pediatric Uveitic Glaucoma. J Glaucoma. 2016;25(9):744-749. doi:10.1097/IJG.0000000000000516</span>
</li>
<li id="cite_note-:11-35"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:11_35-0">35.0</a></sup> <sup><a href="#cite_ref-:11_35-1">35.1</a></sup></span> <span class="reference-text">Wiese K, Heiligenhaus A, Heinz C. Trabekulektomie bei juveniler idiopathischer Arthritis-assoziierter Uveitis: Langzeitergebnisse beim kindlichen Sekundärglaukom [Trabeculectomy in uveitis associated with juvenile idiopathic arthritis: long-term results in pediatric secondary glaucoma]. Ophthalmologe. 2014;111(4):330-338. doi:10.1007/s00347-013-2888-9</span>
</li>
<li id="cite_note-:12-36"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:12_36-0">36.0</a></sup> <sup><a href="#cite_ref-:12_36-1">36.1</a></sup> <sup><a href="#cite_ref-:12_36-2">36.2</a></sup></span> <span class="reference-text">Heinz C, Koch JM, Heiligenhaus A. Trabeculectomy or modified deep sclerectomy in juvenile uveitic glaucoma. J Ophthalmic Inflamm Infect. 2011;1(4):165-170. doi:10.1007/s12348-011-0039-5</span>
</li>
<li id="cite_note-:13-37"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:13_37-0">37.0</a></sup> <sup><a href="#cite_ref-:13_37-1">37.1</a></sup></span> <span class="reference-text">Leinonen S, Kotaniemi K, Kivelä T, Majander A. Potential Effect of Tumor Necrosis Factor Inhibitors on Trabeculectomy With Mitomycin C for Patients With Juvenile Idiopathic Arthritis-Related Uveitic Glaucoma: A Retrospective Analysis. JAMA Ophthalmol. 2015;133(11):1323-1328. doi:10.1001/jamaophthalmol.2015.3387</span>
</li>
<li id="cite_note-:14-38"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:14_38-0">38.0</a></sup> <sup><a href="#cite_ref-:14_38-1">38.1</a></sup></span> <span class="reference-text">Välimäki J, Airaksinen PJ, Tuulonen A. Molteno implantation for secondary glaucoma in juvenile rheumatoid arthritis. Arch Ophthalmol. 1997;115(10):1253-1256.</span>
</li>
<li id="cite_note-:15-39"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:15_39-0">39.0</a></sup> <sup><a href="#cite_ref-:15_39-1">39.1</a></sup></span> <span class="reference-text">Kafkala C, Hynes A, Choi J, Topalkara A, Foster CS. Ahmed valve implantation for uncontrolled pediatric uveitic glaucoma. J AAPOS. 2005;9(4):336-340. doi:10.1016/j.jaapos.2005.04.006</span>
</li>
<li id="cite_note-:16-40"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:16_40-0">40.0</a></sup> <sup><a href="#cite_ref-:16_40-1">40.1</a></sup></span> <span class="reference-text">Bohnsack BL, Freedman SF. Surgical outcomes in childhood uveitic glaucoma. Am J Ophthalmol. 2013;155(1):134-142. doi:10.1016/j.ajo.2012.07.008</span>
</li>
<li id="cite_note-:17-41"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:17_41-0">41.0</a></sup> <sup><a href="#cite_ref-:17_41-1">41.1</a></sup></span> <span class="reference-text">Heinz C, Koch JM, Heiligenhaus A. Transscleral diode laser cyclophotocoagulation as primary surgical treatment for secondary glaucoma in juvenile idiopathic arthritis: high failure rate after short term follow up. Br J Ophthalmol. 2006;90(6):737-740. doi:10.1136/bjo.2005.085936</span>
</li>
<li id="cite_note-42"><span class="mw-cite-backlink"><a href="#cite_ref-42">↑</a></span> <span class="reference-text">Sachdev A, Khalili A, Choi J, Stead RE, Sung VCT. Gonioscopy-assisted Transluminal Trabeculotomy in Uveitic Glaucoma Secondary to Juvenile Idiopathic Arthritis. J Glaucoma. 2020;29(10):e116-e119. doi:10.1097/IJG.0000000000001641</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035200
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.001 seconds
CPU time usage: 0.226 seconds
Real time usage: 1.837 seconds
Preprocessor visited node count: 1000/1000000
Post‐expand include size: 6055/2097152 bytes
Template argument size: 2337/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 1/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 22011/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  673.704      1 Template:Article
100.00%  673.704      1 -total
 83.30%  561.226      4 Template:Infobox_section
 17.64%  118.859      4 Template:UserLookup
 16.04%  108.081      1 Template:Review_expired
  1.31%    8.827      1 Template:Get_active_contest
  0.75%    5.083      1 Template:Infobox_begin
  0.13%    0.875      1 Template:Infobox_end
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Pediatric_Uveitic_Glaucoma&amp;oldid=84526">https://eyewiki.org/w/index.php?title=Pediatric_Uveitic_Glaucoma&amp;oldid=84526</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li><li><a href="/Category:Pediatric_Ophthalmology/Strabismus" title="Category:Pediatric Ophthalmology/Strabismus">Pediatric Ophthalmology/Strabismus</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzyypyj3">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Pediatric_Uveitic_Glaucoma" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Pediatric_Uveitic_Glaucoma" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Pediatric_Uveitic_Glaucoma&amp;oldid=84526" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Pediatric_Uveitic_Glaucoma&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on September 2, 2022, at 05:01.</div>
					<div>This page has been accessed 2,173 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFgAAAAfCAMAAABUFvrSAAACJVBMVEXe3t62trbLy8vGxsbAwMDX19e6urqsrKxHcEzQ0NC2tratra2oqKixsbHd3eDFxcXe3t7U1NTa2trX19fQ0NDV1dWNjY2dnZ2UlJSUlJTS0tKUlJSWlpbR0dGenp79/f38/Pz+/v7t7e3v7+/u7u7s7Oz19fX29vb6+vr7+/vz8/Pz8/P4+fnw8PD39/gWTq/09PX6+vktX7b/sg8XT7F6mc/f5OwhVrNvkMthhsfT2+j7rQ/M1eZqjcmFotPs7e9Cb722xuFResK/zOObstnu7/Grvd3M1+mNqNY6aLoaUbEaUbZWfsTk6fE2Zrnp7O8bTq0kWLQuYcpcg8Xh5/Byk83a4eukud1/nM+6yeQkWcGwwuDxnRQyYrigttvI0+gpW7XGyttLdsBni8geVLo0Z9XlkCPb4u+QqtcfVLLo7PNHcr73phFGX6HsmBnpkxg6bNwnXcbX3er19vnr7/SVrdhuhLl+j70vVqY6Xqv0oxJVcbQhV76DjKTz9ffQ2evE0OZAbbzu7/PS1uFufrDnrGgpSZjy8/SQnMFddrKuekXSiCsgTKRaaZHejy9yang3VptNaqspWbnmliy3j2/m6OzT3e7x8fL4+v3p6uwaN2re0cifqLiLiZWYhYGYb0xXYn+5g0xwiMKYpc2BcHZmW2srRXpGWIhecKfilz4+WID2+PyosMywqbGqss1aVnLZq33p1sGklZqrp7dkfr7CpY9yg59Ud6QZAAAAH3RSTlPfBN/f39/f2wDf39vV3/7N2rrEz5D5c8ONuHaPuXXDImoxqwAABO1JREFUSMe1kQdz01gQgBXaBS4w9OtHwMFSdPKTUNxkW+61xN2Je4tLHJNOGukkAUINJTzaUIbO9fr7TpLtS44DZiC5b6Sn3dW+TysJaWz4cv9eZFPZu/+bhkakYR88WqP59u3vjxzdDCT7GpCD4qNH3sEGzOhB5MCR/4PmA8j25uZ33t0A23lxff5hZTIzOrz2Ph8qK936l7i1tT7hk8DAoHNsbeLWKjPdQcZ+qvX9tHMNXca1XBDXHtL6x2Bh0HWtuXUo8oTgC1gVpcdsdpew92PUYtjwzFq+E9mJYfXxx1x5l2/l5Vhy0DW6TuyQCZcR2hnswXJM0h+203471u5WKMIE5mDpspIIO8sZTMZiIbczY6+JCaI+/sJZ38qjP28+nQjkx/mcqGJ26rW3iKg/fYphCL1jNk5WbqXI0nBnu00RJ2j9bNRp6MmFS0SYIXLuUlQ5w22qizHr5MTyy2u/3XxVvHHlwtWVa/xTCQIIlEaMzrgswzA5P9BrAciYASqNoiNdjL8b0GYAHN3AGAEgzPSQc9UtYCeyBQAMO2G9PhhzXfp9qdifSCT6Lj788QQnrvWEuNPI2um0LW0D+m4A6E4AnIZOeq7ksQuJvi6eUXRW+8EWXsxNPhkYGJiSXr7Rd1qtVp9MXHkgIurzAkdFxjrj7cmKbN4K5v8RGxT2sJMTpwBflNHhUJgBdoUylzy3TuwIDBRi0hf9p9VtbW3qk30X7q2Je1IybZq7mLVWFKTSADXPoqi9AzVorda0kKTS6KkRbSgaR1GT1h5CObYiW1GU27yc5z6F9Fn/yTYedeLi9AIA6AbgxGIxAMPZcZeUHH9cFavVfY97FaNA/DbazRZVV89/61at2BTlg1JXiFtrYoBmRyd7p6/UP0XxaSDmy4pt0jmuh8qx6wQ2MmRz18TaJCUWO9xisUVhMMsoZZDiGHLLuXUbso2iatP/1HvhYu3n3bh6Pe/LUjZSj1NUJ8lSlNwahRRlMRjmyFDICikVn8+SacomdbZTVj+0mQSxweS1WqpiHK/Ncubs858f9idOJ/qKS1cv+RbFuIbMmHEvTbO4QeF25CxyD62nSbmJ1MUzRrpiwR0RPBJMpnCGxWVGXBn8TkarNGQHjuPrxOeWY4GY9FmxWHy19Gvv+ayYF6f8oYi7i8U93bjFkYokvbhWEFu8Og2ZxrUe3NMpc3vLhqqYpVV4XbwDQkpgoVwYKOR9N5d+eXB5vJevQA0pD7oVqi4WOj16vX6EYSA08WKvyeOZJw1cQ6rsnXOa/RYoM0Kls0zLuVoHhHAHL8YFXkwVCoE8uXhvMVCY8mW5Ci8eKkcgJ9azOl0UajNDFiUpj5JeloEqTgwd/iCUJP0sFMSejkpO96b4zl1fPuYiyd6Vs4GBmHSsJoYmLy/WeBTlis5rlJYrgjhe1s+XOXGEtHJOMl4VB2EHLauKdyG7JBLIc//uslRKkhOrcGJqyiU9z5UkOpVOwiGXSyQizRAfqlRc7Y5KJFnV6FReiWSV7xAWeQd/SOSq6qY18eVHq4vjlyazEJ73ScmJPVxJVKdF9MFwYpFIEL+ehvDOcSH8YXRsAa4XfwS7kd0tLfw7Sp7fl7xJywbYjTTVotfTb+849lEcb0K+2lMN/5o+tons+Rxp+PrQ8U3n0BcNSGPj4W+bPuX5ZLNo+uxwY+PfoLJHX1KXgyMAAAAASUVORK5CYII=" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.001},"limitreport":{"cputime":"0.226","walltime":"1.837","ppvisitednodes":{"value":1000,"limit":1000000},"postexpandincludesize":{"value":6055,"limit":2097152},"templateargumentsize":{"value":2337,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":1,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":22011,"limit":5000000},"timingprofile":["100.00%  673.704      1 Template:Article","100.00%  673.704      1 -total"," 83.30%  561.226      4 Template:Infobox_section"," 17.64%  118.859      4 Template:UserLookup"," 16.04%  108.081      1 Template:Review_expired","  1.31%    8.827      1 Template:Get_active_contest","  0.75%    5.083      1 Template:Infobox_begin","  0.13%    0.875      1 Template:Infobox_end"]},"cachereport":{"timestamp":"20230306035200","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":2565});});</script></body>
</html>